The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases

Supportive Care in Cancer

Volumn 22, Issue 7, 2014, Pages 1765-1771

  Lechner, Breanne ^a   DeAngelis, Carlo ^b   Jamal, Noreen ^b   Emmenegger, Urban ^b   Pulenzas, Natalie ^a   Giotis, Angie ^b   Sheehan, Parker ^a   Tsao, May ^a   Bedard, Gillian ^a   Chow, Edward ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bone metastases; Denosumab; Hypocalcemia

Indexed keywords

ALBUMIN; CALCIUM; CLODRONIC ACID; DENOSUMAB; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; DISEASE SEVERITY; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPOCALCEMIA; INCIDENCE; JAW OSTEONECROSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RASH;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CALCIUM; FEMALE; HUMANS; HYPOCALCEMIA; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84902373199     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2142-2     Document Type: Article

References (18)

1. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588-1594
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995-2005
3. Hird A, Zhang L, Holt T, Fairchild A, DeAngelis C, Loblaw A et al (2009) Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for symptomatic bone metastases: a phase II study. Clin Oncol (R Coll Radiol) 21(4):329-335
4. Ford JA, Jones R, Elders A, Mulatero C, Royle P, Sharma P et al (2013) Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer 49(2):416-430
5. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME (2013) Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39(1):97-104
6. XGEVA product monograph (2013) Amgen Canada Inc., Mississauga
7. Skugor M (2009) Hypocalcemia. The Cleveland Clinic Foundation. http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/ hypocalcemia/. Accessed 1 Dec 2013
8. Health Canada. Notice of Compliance Database (2012) Retrieved from http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/nocacc/index-eng.php
9. Anonymous (1977) Correcting the calcium. Br Med 1:598
10. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (2010) National Cancer Institute
11. Ungprasert P, CheungpasitpornW, Srivali N, KittanamongkolchaiW, Bischof EF (2013) Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med 31(4):756
12. Milat F, Goh S, Gani LU, Suriadi C, Gillespie MT, Fuller PJ, Teede HJ, Strickland AH, Allan CA (2013) Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer. Bone 55(2):305-308
13. Body JJ, Lipton A, Henry DH, Stopeck A, Fizazi K, Bone HG, Saad F, Van Poznak CH, De Boer RH et al (2013) Hypocalcemia in patients with metastatic bone disease receiving denosumab. J Clin Oncol (Meeting Abstracts) 31(15), suppl 9628
14. Autio KA, Farooki A, Glezerman I, Chan A, Barr HC, Seyboth BM, Schneider CW, Heller G, Scher HI, Morris MJ (2013) Risk assessment for severe hypocalcemia requiring hospitalization with denosumab. J Clin Oncol (suppl 6; abstr 115)
15. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, TortaM, Porpiglia F, Fontana D, Angeli A (2000) Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164(4):1248-1253
16. Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P (2001) Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 86(9):4133-4138 (Pubitemid 32848525)
17. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813-822
18. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082-3092